2021 Fiscal Year Annual Research Report
Understanding the pathogenesis of right heart failure in pulmonary arterial hypertension
| Project/Area Number |
19K16498
|
|---|
| Research Institution | National Cardiovascular Center Research Institute |
|---|
Principal Investigator |
ワディンガム マーク.トーマス 国立研究開発法人国立循環器病研究センター, 研究所, リサーチフェロー (70822211)
|
|---|
| Project Period (FY) |
2019-04-01 – 2022-03-31
|
| Keywords | Pulmonary Hypertension / Heart Failure / Right Ventricle / Myofilament / Sarcomere / Sympathetic Nervous Sys. / SSRIs |
|---|
| Outline of Annual Research Achievements |
Following on from FY2020 where the selective serotonin re-uptake inhibitor (SSRI), paroxetine, was shown to significantly improve right ventricle systolic function and right ventricle-pulmonary artery coupling in a rat model of severe pulmonary hypertension (PH), the molecular mechanisms underlying this improvement were investigated.
It was shown the paroxetine treatment in PH rats was associated with ~80% higher myosin light chain-2 phosphorylation and significantly increased titin phosphorylation compared to the vehicle-treated PH rats. The changes in titin phosphorylated correlated with increased RV function.
|
